Table 1.
Characteristics of included patients
| All (n = 42) | DVT present (n = 8) | DVT absent (n = 34) | p | |
|---|---|---|---|---|
| Age (year) | 64.6 + 19.3 | 77.7 + 15.2 | 61.5 + 19.0 | 0.02* |
| Male sex, no. (%) | 23 (54.8) | 4 (50) | 19 (55.9) | 1 |
| BMI (kg/m2) | 28 (23.9–32) | 21.9 (19.4–26.9) | 28 (23.9–32) | 0.16 |
| Median time (IQR) from hospitalization to CDU (days) | 4 (2–6) | 6 (4.2–8.2) | 3 (2–6) | 0.16 |
| Median time (IQR) from symptom onset to CDU (days) | 11 (8–15.7) | 14 (9.5–26.2) | 10.5 (7.2–15) | 0.16 |
| Comorbidities, no.(%) | ||||
| Hypertension | 20 (47.6) | 6 (75) | 14 (41.2) | 0.12 |
| Diabetes | 13 (31) | 3 (37.5) | 10 (29.4) | 0.69 |
| Cardiovascular dieases | 7 (16.7) | 2 (25) | 5 (14.7) | 0.6 |
| Current smoking | 5 (11.9) | 1 (12.5) | 4 (11.8) | 1 |
| Active cancer | 3 (7.1) | 1 (12.5) | 2 (5.9) | 0.48 |
| RT-PCR positive for COVID-19, no. (%) | 33 (78.6) | 5 (62.5) | 28 (82.4) | 0.3 |
| Stage of imaging, no.(%) | ||||
| Mild | 7 (16.7) | 1 (12.5) | 6 (17.6) | 0.56 |
| Moderate | 23 (54.8) | 4 (50) | 19 (55.9) | |
| Severe | 8 (19) | 3 (37.5) | 5 (14.7) | |
| Missing data | 4 (9.5) | 0 (0) | 4 (11.8) | |
| Anticoagulation, no.(%) | ||||
| Usual prophylactic doses | 25 (59.5) | 4 (50) | 21 (61.8) | 0.26 |
| Intermediate prophylactic doses | 10 (23.8) | 1 (12.5) | 9 (26.5) | |
| Therapeutic doses | 7 (16.7) | 3 (37.5) | 4 (11.8) | |
| DVT, no. (%) | ||||
| Proximal | – | 1 (12.5) | – | – |
| Distal | – | 7 (87.5) | – | |
| 1 vein affected | – | 3 (37.5) | – | |
| 3 veins affected | – | 3 (37.5) | – | |
| 4 veins affected | – | 1 (12.5) | – | |
| 5 veins affected | – | 1 (12.5) | – | |
| Femoro-popliteal vein | – | 1 (12.5) | – | |
| Peroneal vein | – | 6 (75) | – | |
| Posterior tibial vein | – | 3 (37.5) | – | |
| Soleus vein | – | 5 (62.5) | – | |
| PE, no. (%) | ||||
| All | 4 (9.5) | 1 (12.5) | 3 (8.8) | – |
| Right sided | 3 (75) | 1 | 2 | |
| Bilateral | 2 (50) | 0 | 2 | |
| Proximal | 0 (0) | 0 | 0 | |
| Segmental or sub-segmental | 4 (100) | 1 | 3 | |
| Outcome no. (%) | ||||
| Hospitalisation | 3 (7.1) | 2 (25) | 1 (2.9) | 0.009* |
| Discharged | 34 (81) | 4 (50) | 30 (88.2) | |
| ICU | 3 (7.1) | 0 (0) | 3 (8.8) | |
| Died | 2 (4.8) | 2 (25) | 0 (0) | |
| d-dimer (μg/ml) | 1414 (951–3946) | 1988 (1374–6453) | 1253 (873–3432) | 0.11 |
| Fibrinogen (g/l) | 5.70 (4.87–6.68) | 6.06 (5.10–6.49) | 5.60 (4.82–6.76) | 0.73 |
| CRP (mg/l) | 85 (45–121) | 90 (50–138.8) | 85 (45–121) | 0.99 |
| Prothrombin ratio (%) | 79 (70–84.75) | 80.5 (77–82.5) | 79 (67–88) | 0.39 |
| APTT ratio | 1.100 (1.008–1.192) | 1.100 (1.008–1.192) | 1.100 (1.015–1.160) | 0.97 |
| Interleukin-6 (mg/l) | 42.75 (20.95–100.35) | 216.8 (216.8–216.8) | 38.50 (19.70–81.15) | 0.2 |
| Leukocyte count (per mm3) | 7.65 (6.10–12.4) | 8.65 (6.15–13.62) | 7.65 (6.10–10.60) | 0.61 |
| Hemoglobin (g/dl) | 12 (10.3–12.8) | 11.5 (10.6–12.2) | 12.2 (10.3–13.2) | 0.36 |
| Platelet count (109/l) | 258 (166–395) | 183 (158–285) | 275 (170–318) | 0.21 |
| Lymphocyte count (per mm3) | 0.89 (0.66–1.22) | 0.8 (0.53–1) | 0.89 (0.7–1.01) | 0.33 |
| Albumine (g/l) | 27 (23–32) | 25.5 (23.75–30) | 28 (23–32.5) | 0.84 |
| SPO2 (%) | 92.5 (90–95) | 89 (87–93) | 93 (90–95) | 0.17 |
| PaO2 (mmHg) | 73 (63–82) | 70 (58–84) | 73 (63–81) | 0.84 |
*p < 0.05